Trimel Pharma's sexual disorder drug effective in mid-stage study

(Reuters) - Trimel Pharmaceuticals Corp said its experimental sexual disorder drug increased the average number of orgasms in patients with Female Orgasmic Disorder in a mid-stage study. The company said a 0.6 mg dose of the nasal drug, Tefina, showed a statistically significant increase in the number of orgasms in pre-menopausal and post-menopausal patients with the condition, compared with a placebo. Female Orgasmic Disorder, also known as anorgasmia, is characterized by a delay, absence or reduced intensity of orgasm, leading to distress.



via Health News Headlines - Yahoo News http://ift.tt/1tOtkYb